 |
|
|
| |
Treatment of Hepatitis C Genotype 1 Patients with Severe Fibrosis or Compensated Cirrhosis: The International Telaprevir Early Access Program
|
| |
| |
Reported by Jules Levin
AASLD Nov 9-13 2012 Boston
M Colombo1, I Fernandez2, D Abdurakmnov3, PA Ferreira4, S Strasser5, P Urbanek6, C Moreno7, A Streinu-Cercel8, A Verheyen9, W Iraqi10, R DeMasi11, A Hill12, JM Lauffer12, I Lonjon-Domanec13, H Wedermeyer14
1Dept of Medicine, Div of Gastroenterology, Fondazione IRCCS Ca Granda Ospedale Maggiore Policclinico, Universita degli Studi de Milano, Milan, Italy; 2Hospital Universitario12 de Octubre, Seccion de Aparato Degistivo, Madrid, Spain; 3EM Tareev Clinic for Nephrology, Internal and Occupational Medicine, Moscow, Russia; 4 Outpatient Clinic to HIV and Viral Hepatitis Division of Infectious Disease, Federal University of Sao Paulo, Sao Paulo, Brazil; 5Royal Prince Alfred Hospital, University of Sydney, Sydney, Australia; 6Dept of Internal Medicine, First Medical Faculty, Charles University, and Central Military Hospital Prague, Prague, Czech Republic; 7Dept of Gastroenterology and Hepatopancreatology, Hopital Erasme, Universite Libre de Bruxelles, Brussels, Belgium; 8University of Medicine Bucharest and National Institute for Infectious Disease Matei Bals, Bucharest, Romania; 9Janssen Pharmaceutica, Beerse, Belgium; 10Janssen Pharmaceuticals, Paris, France; 11Tibotec Inc, Titisville, NJ USA; 12MetaVirology Ltd, Lonod , UK; 13Janssen-Cilag AG, Baar, Switzerland; 14Medizische Hochschule Hannover, Hannover, Germany.
|
| |
|
|
|
|
|
